Oncology

Guidelines typically recommend debulking surgery, plus systemic chemotherapy for most patients.

The oncology space has seen rapid growth in the last decade, with new approvals and indications necessitating expertise in areas such as medication use, safe practices, and reimbursement practices.

Understanding breast cancer and which patients may be more vulnerable to long-term treatment effects and which patients may benefit most, can help oncologists design the best personalized neoadjuvant and adjuvant human epidermal growth factor receptor 2 (HER2)-targeted therapy.

A panel of experts in neuroendocrine tumors review the challenges in the management of patients based on the site of the tumor.

Modifications include high rates of neoadjuvant endocrine chemotherapy, genomic assay testing on core biopsies, and delays in planned surgeries.

The study, conducted by investigators from the Breast Cancer Surveillance Coalition (BCSC), had an objective to quantify the impact of the COVID-19 pandemic on both breast cancer screening and diagnostic mammography services in the United States.

Bariatric surgery can significantly reduce the risk of cancer—and especially obesity-related cancers—by as much as half in individuals with severe obesity and nonalcoholic fatty liver disease (NAFLD), according to a study by researchers at Rutgers Robert Wood Johnson Medical School's Center for Liver Diseases and Liver Masses.

In a Pharmacy Times® Peer Exchange video series, experts discussed the current landscape and management of relapsed or refractory multiple myeloma (RRMM), including the latest data and potential treatment strategies on the horizon.

In this high-risk population, strategies for minimizing viral exposure during a pandemic are being considered with oncology treatment options.

Megan May, PharmD, BCOP, reviews the authorization process for treatment options for the management of NETs.

Isatuximab in combination with carfilzomib and dexamethasone reduced the risk of disease progression or death by 45% versus standard of care alone.

The study also analyzed the relationship between ultra-processed food and drink products with 2 other cancer types.

Although pediatric patients represent a small portion of total acute myeloid leukemia cases, clinicians said there is a critical need for more effective therapies in this population.

Panelists review the challenges in managing VTE.

In England, incidence rates of the skin cancer cutaneous malignant melanoma were found to have increased by more than 550% among males and 250% among females since the early 1980s.

Experts in the management of NETs share the challenges of getting therapeutic agents on the formulary.

The studies had a minimum follow-up period of 24 weeks and reported at least 1 event of breast cancer or benign breast neoplasm, which included 90,360 participants.

In a clinical trial of idecabtagene vicleucel in multiple myeloma, the overall response rate for the efficacy evaluable population was 72%, and 28% of participants achieved a stringent complete response.

The analysis found that more than twice as many women who received olaparib were still alive 5 years after the beginning of the study with no progression of their cancer.

Mitchell Horwitz, MD, principal investigator and professor of medicine at the Duke Cancer Institute, discusses the results of a phase 3 study of omidubicel, which treats patients with hematologic malignancies in need of a bone marrow.

In addition to cardiotoxicity from cancer-related treatments, the researchers noted that obesity, cancer, and cardiovascular disease share some common risk factors.

DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, which activates the innate immune system in the tumor microenvironment and anti-tumor activity.

A new study published in The American Journal of Clinical Nutrition found that for colorectal cancer survivors, maintaining a stable body weight may hide a loss of muscle and the development of fatty deposits in their muscles, which resulted in a 40% higher risk of premature death.

With the breakthrough device designation granted in 2019, the Signatera MRD test now has 3 designations for use across several cancer types and indications.

Results from the phase 3 KEYNOTE-775/study 309 trial found that Keytruda plus Lenvima reduced risk of death by 38%, with a median overall survival of 18.3 months

Results from a phase 3 trial investigating the programmed cell death protein 1 inhibitor cemiplimab monotherapy compared to chemotherapy showed an overall survival benefit among patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.

Electricity may slow the speed at which breast cancer cells spread through the body, and in some cases may stop them entirely, according to a new study published in Bioelectricity.

When analyzing the odds of death or hospitalization due to COVID-19, the researchers found that use of cytotoxic chemotherapy did not predict increased risk for either.